argenx SE (NASDAQ: ARGX), a dynamic player in the biotechnology sector, is garnering substantial attention from investors thanks to its impressive growth metrics and strong market presence. With a market capitalization of $52.25 billion, this Netherlands-based biopharma company is making waves in the healthcare industry with its innovative therapies targeting autoimmune diseases across the globe.

At its current price of $844.41, argenx SE maintains a strong foothold within its 52-week range of $532.27 to $929.61. Despite a recent price change of -2.85, the stock’s trajectory remains promising, particularly given the consensus among analysts who have set an average target price of $1,029.29. This suggests a potential upside of…